Paclitaxel Poliglumex
| Code | Size | Price |
|---|
| TAR-T20265-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Paclitaxel Poliglumex is cyclohexane isolated from the bark of the Pacific yew tree.
CAS:
263351-82-2
Formula:
C52H60N2O18
Molecular Weight:
1001.048
Purity:
0.98
SMILES:
N[C@@H](CCC(O)=O)C(O)=O.CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1
References
1. Markovsky E, Eldar-Boock A, Ben-Shushan D, Baabur-Cohen H, Yeini E, Pisarevsky E, Many A, Aviel-Ronen S, Barshack I, Satchi-Fainaro R. Targeting NCAM-expressing neuroblastoma with polymeric precision nanomedicine. J Control Release. 2017 Mar 10;249:162-172. doi: 10.1016/j.jconrel.2017.01.044. Epub 2017 Feb 1. PubMed PMID: 28159518.
2. Elinzano H, Glantz M, Mrugala M, Kesari S, Piccioni DE, Kim L, Pan E, Yunus S, Coyle T, Timothy K, Evans D, Mantripragada K, Boxerman J, DiPetrillo T, Donahue JE, Hebda N, Mitchell KM, Rosati KL, Safran H. PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study: BrUOG 244. Am J Clin Oncol. 2018 Feb;41(2):159-162. doi: 10.1097/COC.0000000000000247. PubMed PMID: 26658237.
3. Chow W, Amaya CN, Rains S, Chow M, Dickerson EB, Bryan BA. Growth Attenuation of Cutaneous Angiosarcoma With Propranolol-Mediated ?-Blockade. JAMA Dermatol. 2015 Nov;151(11):1226-9. doi: 10.1001/jamadermatol.2015.2554. PubMed PMID: 26375166.
4. Boxerman JL, Ellingson BM, Jeyapalan S, Elinzano H, Harris RJ, Rogg JM, Pope WB, Safran H. Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma. Am J Clin Oncol. 2017 Jun;40(3):228-234. doi: 10.1097/COC.0000000000000156. PubMed PMID: 25436828.